Interpace Biopharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Interpace Biosciences Announces Divestiture of New Haven CLIA lab to DiamiR March 17, 2021 07:30 ET | Source: Interpace Biosciences, Inc. Interpace Biosciences, Inc. Part of Company’s Site Consolidation and Cost Savings Measures Parsippany, NJ, March 17, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTC: IDXG) announced today that it has entered into a definitive agreement to sell its New Haven CT CLIA certified, CAP accredited laboratory to DiamiR Biosciences, Corp. (DiamiR). This sale is in line with previously announced restructuring and cost reduction...

DiamiR Announces Acquisition of CLIA Lab from Interpace Biosciences News provided by Share this article Share this article MONMOUTH JUNCTION, N.J., March 17, 2021 /PRNewswire/ -- DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced that it has entered into a definitive agreement to acquire a CLIA (Clinical Laboratory Improvement Amendments) certified laboratory in New Haven, CT from Interpace Biosciences, Inc. Subject to specific terms and conditions of the agreement being met, it is anticipated that the transaction will close by ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Interpace Biosciences Announces License Agreement with Rutgers University and Mass General Hospital Interpace Biosciences, Inc.February 1, 2021 GMT Parsippany, NJ, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) announced today that it has executed a license agreement with Rutgers, The State University of New Jersey, and Massachusetts General Hospital for a novel monoclonal antibody platform, Das-1, used in the risk assessment of pancreatic cysts. Although some cysts ma...